I-Corps: Barcode Blotting Diagnostic Technology for Point-of-Care Testing

发达国家和发展中国家慢性传染病的扩散表明，迫切需要使目前缓慢的、劳动密集型的实验室诊断方法更便宜、更便携，并具有必要的灵敏度和特异度，以用于现场诊断分析。加州大学伯克利分校开发的集成条形码诊断工具显著降低了检测成本和时间，同时为健康从业者提供关于疾病状态的关键新信息，以便准确地现场筛查和治疗包括艾滋病毒/丙型肝炎(丙型肝炎)合并感染在内的传染病。拟议的工作将使原型制作、需求评估和收集客户和行业反馈，从而开发出第一个用于全血生物标记物免疫分析的多重电泳法平台。该团队的核心技术是三维水凝胶基质，可以捕获和检测特异性抗体(IgG)。存在引入集成诊断平台技术的机会，该集成诊断平台技术保留了当前筛查诊断的低成本、小占地面积、易用性和便携性，同时增加了目前在大型集中式实验室中运行的缓慢、人工劳动密集型确证诊断所提供的高特异性(准确性)。生物功能化聚丙烯酰胺光图案化技术的关键进展提供了一种操作简单、快速的多重条形码印迹免疫分析方法。将复杂和高性能的分析转化为单一的低成本便携式工具可以显著提高艾滋病毒和丙型肝炎(丙型肝炎)的诊断水平。将条形码印迹技术商业化，用于快速(30分钟)和多路复用的艾滋病毒/丙型肝炎筛查诊断，将为改善世界医疗保健做出重大贡献，同时还将进入一个商业市场，为未来几年的显著增长做好准备。

The proliferation of chronic infectious diseases in the developed and developing world demonstrates the vital need to make presently slow and labor intensive laboratory diagnostics cheaper and more portable with the requisite sensitivity and specificity to be deployed as field diagnostic assays. The integrated barcode diagnostic tool developed at UC Berkeley significantly reduces assay cost and time while providing health practitioners with critical new information on disease state for accurate on-the spot screening and treatment of infectious diseases including HIV/HCV (hepatitis C) co-infection. The proposed work will enable prototyping, needs assessment and collection of customer and industry feedback towards development of the first multiplexed electrophoretic platform for immunoassay of biomarkers from whole blood. The team's core technology is a three-dimensional hydrogel matrix which enables specific antibody (IgG) capture and detection. There exists an opportunity to introduce an integrated diagnostic platform technology preserving the low cost, small footprint, ease-of-use and portability of current screening diagnostics while adding the high-specificity (accuracy) provided by slow, manual-labor intensive confirmatory diagnostics that are presently run in large centralized laboratories. The key advances in biologically-functionalized polyacrylamide photo-patterning technology provide a multiplexed barcode blotting immunoassay with simple and fast operation. Transforming sophisticated and high performance assays into a single low-cost portable tool can significantly advance diagnosis of HIV and hepatitis C (HCV). Commercializing the barcode blotting technology for rapid (30 min) and multiplexed HIV/HCV screening diagnostics would make a major contribution to improving world healthcare while also providing entry into a commercial market primed for significant growth over the next several years.